January 17, 2019
In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic.
According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing...
October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics.
On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...
October 10, 2018
Children’s Health, a Texas-based pediatric health system, is teaming up with Proteus to pilot a new program aimed at tackling adherence issues in pediatric heart transplant patients by inserting ingestible sensors into prescribed pills, which can track when the medication was taken.
The system is made up of a wearable patch worn by the patient and the sensor-infused pill. When the pill is broken...
August 30, 2018
Otsuka Pharmaceuticals and Proteus Digital Health’s sensor-carrying pill Abilify MyCite is on its way to US patients thanks to a new collaboration agreement between Otsuka and Magellan Health. Announced this morning by the pharmaceutical company, the rollout will initially be limited to give Otsuka and Magellan a better idea of how best to deploy the technology at scale.
“We are eager for...
August 21, 2018
Anthem Blue Cross and Blue Shield in Ohio has partnered with Propeller Health to provide sensor-equipped inhaler attachments to plan members with COPD. The rollout will give members access to Propeller’s medication tracker app, while providing an online provider portal for the insurer’s care management team.
“There’s currently no cure for COPD, but much can be done to help consumers treat the...
July 26, 2018
Proteus Digital Health’ pitch to track adherence using sensor-equipped pills has found another audience in the HIV prevention community.
Among the featured data presented at this week’s International AIDS Conference in Amsterdam was a trial that outfitted Gilead Sciences’ preventive HIV drug Truvada (tenofovir/emtricitabine) with the tracking technology. Here, researchers found that the sensor-...
March 8, 2018
It’s still the early days, but the FDA’s approval of Proteus Digital Health and Otsuka Pharmaceuticals’ Abilify MyCite has changed the discussion of digital technology in healthcare. The first approval of drug delivery via a sensor-equipped pill sparked debates over the tradeoff of privacy for medication adherence, and whether these types of technologies would find a role in future healthcare....
November 14, 2017
The first drug in the US with a digital ingestion tracking system has been approved by the FDA.
The pill, Abilify MyCite, is prescribed for treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and as an add-on treatment for depression in adults.
An ingestible sensor embedded in the pill is able to record that the medication was taken – sending...
June 13, 2016
Digital health and digital therapeutics will produce a tremendous amount of data, which could be the key to getting them reimbursed by payers, according to panelists at BIO 2016 last week. UCSF Professor of Health Economics and Health Services Research Kathryn Phillips led a panel that included Rowan Chapman, managing director of new business ventures at GE Ventures; Evidation Health CEO Deborah...
April 27, 2016
The FDA declined to approve what would have been the first mass market drug to incorporate Proteus Digital Health's ingestible sensor. The drug, a collaboration between Proteus and Otsuka Pharmaceuticals, combines the Proteus system with the antipsychotic pharmaceutical Abilify.
“While we are disappointed in the FDA’s decision not to approve this digital medicine at this time, both Otsuka and...